Martin Jadersten
Overview
Explore the profile of Martin Jadersten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1825
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gyan E, Minden M, Kubo K, Rambaldi A, Juliusson G, Jadersten M, et al.
Cancer
. 2025 Feb;
131(4):e35746.
PMID: 39945223
Background: The GOSSAMER phase 2 study assessed the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib as maintenance therapy in patients with FLT3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) in...
2.
Rasmussen B, Nilsson L, Tobiasson M, Jadersten M, Garelius H, Dybedal I, et al.
Genes Chromosomes Cancer
. 2025 Feb;
64(2):e70029.
PMID: 39921387
In myelodysplastic syndromes (MDS), cytogenetic characteristics of the malignant bone marrow cells influence the clinical course. The aim of this study was to evaluate whether cytogenetics is useful to predict...
3.
Lundstrom J, Wiqvist S, Jadersten M, Tollemar V, Legert K
Support Care Cancer
. 2024 Oct;
32(10):703.
PMID: 39370491
Purpose: Benefits of prophylactic platelet (PLT) transfusion before dentoalveolar surgery are unclear. This study investigated the effect of prophylactic PLT transfusions on the incidence of postoperative bleeding (POB) in patients...
4.
Crisa E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymaki M, et al.
Leukemia
. 2024 Aug;
38(10):2259-2265.
PMID: 39103678
Lenalidomide (LEN) can induce red blood cell-transfusion independence (RBC-TI) in 60-70% of del(5q) myelodysplastic neoplasm (MDS) patients. Current recommendation is to continue LEN in responding patients until failure or progression,...
5.
Bernard E, Hasserjian R, Greenberg P, Arango Ossa J, Creignou M, Tuechler H, et al.
Blood
. 2024 Jul;
144(15):1617-1632.
PMID: 38958467
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic abnormalities underlie the pathogenesis of these disorders and their heterogeneity, current...
6.
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa J, et al.
Blood
. 2024 Apr;
144(11):1221-1229.
PMID: 38687605
Mutations in UBA1, which are disease-defining for VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, have been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here, we define the prevalence...
7.
Creignou M, Bernard E, Gasparini A, Tranberg A, Todisco G, Moura P, et al.
J Intern Med
. 2024 Apr;
296(1):53-67.
PMID: 38654517
Background: The Molecular International Prognostic Scoring System (IPSS-M) is the new gold standard for diagnostic outcome prediction in patients with myelodysplastic syndromes (MDS). This study was designed to assess the...
8.
Bernard E, Tuechler H, Greenberg P, Hasserjian R, Arango Ossa J, Nannya Y, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200008.
PMID: 38319256
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are...
9.
Tobiasson M, Pandzic T, Illman J, Nilsson L, Westrom S, Ejerblad E, et al.
J Clin Oncol
. 2024 Jan;
42(12):1378-1390.
PMID: 38232336
Purpose: Clinical relapse is the major threat for patients with myelodysplastic syndrome (MDS) undergoing hematopoietic stem-cell transplantation (HSCT). Early detection of measurable residual disease (MRD) would enable preemptive treatment and...
10.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong I, et al.
Blood Adv
. 2023 Dec;
8(2):343-352.
PMID: 38039513
Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can...